Clinical correlates ofJAK2V617F allele burden in essential thrombocythemia-Reference-Cited by-同舟云学术

Clinical correlates ofJAK2V617F allele burden in essential thrombocythemia

Published:2007 Issue:11 Volume:109 Page:2279-2284
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kittur Jaya,Knudson Ryan A.,Lasho Terra L.,Finke Christy M.,Gangat Naseema,Wolanskyj Alexandra P.,Li Chin-Yang,Wu Wenting,Ketterling Rhett P.,Pardanani Animesh,Tefferi Ayalew

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders

2. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera

3. JAK2V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

4. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study

5. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular testing in myeloproliferative neoplasms;Diagnostic Molecular Pathology;2024

2. Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms;Turkish Journal of Hematology;2023-09-01

3. Essential thrombocythemia: challenges in clinical practice and future prospects;Blood;2022-11-15

4. Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients;Medical Bulletin of Haseki;2022-01-01

5. The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders;British Journal of Haematology;2021-08-18